Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Glutathione** is an endogenous reduced tripeptide antioxidant composed of glutamate, cysteine, and glycine. Administered glutathione replenishes thiol-based cellular redox capacity and serves as a substrate for glutathione peroxidases and glutathione S-transferases, supporting detoxification of reactive oxygen species, peroxides, and electrophilic metabolites. It has been used or studied as a cytoprotective adjunct through oral, intravenous, inhaled, and intranasal delivery, including for chemotherapy-associated toxicities, cystic fibrosis, and Parkinson's disease. Clinical evidence for disease-modifying or symptomatic benefit remains limited and route-specific. A 2024 retrospective breast-cancer analysis associated prolonged oral glutathione exposure during chemotherapy with poorer outcomes, so use during cytotoxic chemotherapy requires particular clinical caution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glutathione.